Translation in der Nanomedizin. "Qualitative Indikatoren" der medizinischen Innovationsforschung in der Europäischen Union

纳米医学翻译。

• 批准号: 432916842
• 负责人: Professor Dr. Christian Papilloud
• 金额: --
• 依托单位: Institut für Soziologie
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 2021-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/432916842?language=en
• 关键词: Translation; der; Nanomedizin.; Qualitative; Indikatoren

This subproject deals with the future assessment of innovation and innovation research. It qualitatively examines the genesis, usage and consequences of a procedure aiming at evaluating research projects in nanomedicine in Europe on the basis of -- as the actors in this procedure name them -- qualitative indicators, i.e. not-indicators as stated in this project's overarching framework. This procedure has been brought about by the EU platform ETPN (European Technology Platform Nanomedicine) and the EU network ENATRANS (Enabling Nanomedicine Translation). They aim at facilitating and increasing cooperation between science and industry in nanomedicine throughout Europe. This procedure was organised according to the translation assessment (2016-2017) within the framework of a first prototype test phase. This test phase was about building a Translation Advisory Board (TAB) with selected experts from different European countries, who should work on a prototypical qualitative procedure for the evaluation of selected research projects in Europe. At the end of 2017, a systematising test phase has been launched for three years (2018-2021) within the framework of the European Coordination and Support Action NOBEL. Based on the results of the first test phase, the TAB experts construct "qualitative indicators" which they apply to nanomedical research projects selected after an application procedure. This subproject analyses this procedure empirically, starting with and going beyond NOBEL following four steps: a) the methodological basis on which these qualitative indicators are constructed; b) how these indicators take into account the phases of mandatory clinical testing; c) how these indicators take into account the requirements of enterprises/companies/industries in relation to the research projects being evaluated; d) how this qualitative procedure compares to benchmark studies and other quantitative indicators of technological innovation for assessing the sustainability of nanomedicine. These four steps conclude in answering this subproject's framing question, how the relation between experts influences the construction and usage of qualitative indicators in the evaluation procedure and how this affects the sustainability of nanomedicine in Europe.

这个分项目涉及对创新和创新研究的未来评估。它从质量上研究的起源，用途和后果的程序，旨在评估研究项目在纳米医学在欧洲的基础上-在这个程序中的演员命名他们-质量指标，即不指标，在这个项目的总体框架。这一程序是由欧盟平台ETPN（欧洲纳米医学技术平台）和欧盟网络ENATRANS（使能纳米医学翻译）提出的。他们的目的是促进和增加整个欧洲纳米医学科学和工业之间的合作。该程序是根据第一个原型测试阶段框架内的翻译评估（2016-2017）组织的。这个测试阶段是关于建立一个翻译咨询委员会（TAB），由来自不同欧洲国家的专家组成，他们应该为欧洲选定的研究项目的评估制定一个原型定性程序。2017年底，在欧洲协调和支持行动NOBEL框架内启动了为期三年（2018-2021）的系统化测试阶段。根据第一阶段的测试结果，TAB专家构建了“定性指标”，并将其应用于申请程序后选择的纳米医学研究项目。这个子项目从NOBEL开始并超越以下四个步骤对这一程序进行经验分析：a）构建这些定性指标的方法学基础; B）这些指标如何考虑到强制性临床试验的阶段; c）这些指标如何考虑到企业/公司/行业对被评价研究项目的要求; d）如何将这种定性程序与基准研究和其他技术创新的定量指标进行比较，以评估纳米医学的可持续性。这四个步骤的结论是回答这个子项目的框架问题，专家之间的关系如何影响评估过程中定性指标的构建和使用，以及这如何影响欧洲纳米医学的可持续性。